Scale Up of Therapeutic Viral Vectors for Gene Therapy with PALL

Phacilitate
28 October 2021
SHARE NOW
Scaling up therapeutic viral vectors for gene therapy to meet clinical trial and market needs.

PLAY VIDEO ABOVE * PALL, the sponsor of this content would like to send you information about their products and services. If you do not wish to receive these emails, click here to opt out.

“When we think about cell and gene therapy scaling and industrialisation, one question that needs to be answered is what scale is needed to match the therapy demand?”

For this technology demonstration, Emmanuelle Cameau, Viral Vector & Gene Therapy Technical Manager at PALL Corporation, outlines how to match manufacturing scale to therapy demand, providing example calculations for defining your manufacturing platform and scale before discussing the overall concept of scaling up therapeutic viral vectors for gene therapy in the context of PALL’s services, through case studies.

Phacilitate member? Watch this video and join the conversation via the network.

Not yet a member?
Join Today.